Portfolio company
Sightera
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
Sightera develops an artificial intelligence platform for drug discovery to design small-molecule therapies for oncology and fibrosis patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Sightera Biosciences
Sightera Biosciences develops AI-designed small molecule drugs for pharmaceutical partners and patients with therapy-resistant cancer and fibrosis.
innovothera
This biotechnology company develops small-molecule therapies for fibrosis, inflammatory diseases, and cancer using an artificial intelligence drug discovery platform.
Xaira
The company develops artificial intelligence platforms to design and develop antibody-based medicines for patients with various diseases.
Auron Therapeutics
This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.
Exscientia
Exscientia develops an artificial intelligence platform to design and discover small-molecule drug candidates for pharmaceutical and biotechnology companies.
Serna Bio
This company develops an AI-native platform to discover small molecule drugs targeting RNA for pharmaceutical partners treating respiratory and other complex diseases.
Ten63 Therapeutics
This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.
PsiThera
PsiThera develops oral small-molecule medicines for patients with immune and inflammatory diseases, using a physics-driven platform to target proteins traditionally requiring injections.